HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

Lifordi Immunotherapeutics, Inc., today announced that it has received the Endpoints 11 Award from Endpoints News, an honor ...

AbbVie on Friday said the application covers telisotuzumab vedotin, or teliso-V, in adults with previously treated, locally advanced or metastatic epidermal growth factor receptor wild type, ...

AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in ...

In October 2019, Janet Woodcock, then the director of the US Food and Drug Administration’s Center for Drug Evaluation and ...

Zymeworks is awaiting key regulatory decisions for zanidatamab, with potential EU and China approvals following. Read more ...

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.

Legend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.

BioNTech has launched global clinical trials for BNT116, an mRNA vaccine designed to treat non-small cell lung cancer.

NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the ...

The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UKSAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE ...

AbbVie Inc. (NYSE:ABBV) is well-positioned to deliver a top-tier long-term outlook, driven by Humira’s success and strategic ...